
Once dominated by Western markets, China and India are now emerging as leaders in small molecule development.
Indeed, they are leading the way in developing not just lower-cost ‘me-too’ drugs, but also in delivering truly innovative first-in-class and best-in-class therapies.
Small molecule drugs now account for the largest share of new drug approvals in Eastern markets, as detailed by a report from PharmCube.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze